OLMA News and Press, Olema Pharmaceuticals Inc. From 09/05/23

$130 million equity private placement led by Paradigm BioCapital with participation by Lightspeed Venture Partners, Deep Track Capital, BVF Partners L.P., Cormorant Asset Management, Vivo Capital, Logos Capital, and Woodline Partners LP Senior secured credit facility for up to $50 milli...

2023-08-20 02:57:33 ET Summary Olema Pharmaceuticals has gained almost 30% since 1H 2023, outperforming XBI by 80%. The company's OP-1250 combination therapy for ER+ breast cancer showed promising results in a Phase 1b/2 study. Olema's strong financial position, upcoming catal...

2023-08-08 17:54:51 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q2 GAAP EPS of -$0.49 beats by $0.25 . Cash, cash equivalents and marketable securities as of June 30, 2023, were $167.4 million, a reduction of approximately $18.6 million from the quarter en...

Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarter New clinical data for palazestrant (OP-1250) to be presented in the fourth quarter including both monotherapy and CDK4/6 inhibitor combination updates Ca...

SAN FRANCISCO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for womenȁ...

2023-06-09 14:37:00 ET Gainers: Blue Apron Holdings ( APRN ) +65% . Sientra ( SIEN ) +50% . ContraFect ( CFRX ) +43% . Global Indemnity ( GBLI ) +23% . Disc Medicine Opco ( IRON ) +21% . Olema Pharmaceuticals ( OLMA ) +...

SAN FRANCISCO, May 30, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s c...

2023-05-19 16:30:24 ET Summary OLMA Overview: A clinical-stage biopharmaceutical company targeting ER+ breast cancer. The lead candidate, OP-1250, is a dual-function oral therapy promising deeper responses and treatment resistance mitigation. Pipeline Potential: OLMA's drugs, espe...

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction Overall tolerability profile of the combination is consistent with the FDA-approved label of palbociclib ...

2023-05-09 18:04:59 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q1 GAAP EPS of -$0.70 misses by $0.04 . Cash, cash equivalents and marketable securities as of March 31, 2023, were $186.0 million. Olema anticipates that this balance will be suffic...